Adherium appoints CEO to drive global growth

Adherium, a digital health technology company looking to address the sub-optimal medication use in chronic diseases, announced the appointment of Arik Anderson as Group CEO.

Founder and previous Group CEO, Garth Sutherland, welcomed the appointment of Arik as a key step in the next and important phase of Adherium’s global business growth, allowing him to focus on new areas of development while Mr Anderson focusses on the global business opportunities in front of the Company today.

Mr Sutherland, Adherium Founder, said: “Adherium is very fortunate to attract someone of Arik’s standing, he is ideally suited to lead the company into its commercial growth phase as we focus on expanding our global footprint.

“We welcome him to our team, his industry experience, combined with our award-winning Smartinhaler products and technology platform, will allow Adherium to further build upon its position as a market leader in the digital health space. His arrival will also allow me more time to focus on areas of new product development that I have been wanting to undertake for some time now.”

This transition of control at the top of the Company is a very considered step by the board and as a key part of the transition Mr Sutherland, in the interim, will remain an Executive Director on the Adherium Board.

With more than 25 years of experience in the medical technology and medical device manufacturing industries, Mr Anderson has led significant growth for emerging technology companies.

Most recently, Mr Anderson was President of Perfusion and Surgical Devices at Terumo Cardiovascular Systems, responsible for a US$300M portfolio of devices used in the surgical operating room, which was sold in more than 170 countries.

Mr Anderson retains board positions on the University of Michigan Medical School MTRAC Board, which oversees investment in medical technology, and the University of Michigan Ross School of Business Zell Lurie Healthcare Board, which oversees student investment in emerging technology via the Zell Lurie Commercialisation Fund.

Mr Anderson, Adherium CEO, said: "Adherium’s digital health solutions are already having a positive impact on the health of people with respiratory disease globally. I look forward to leading the organisation to bring the benefits of Smartinhaler to patients world-wide.”

Mr Anderson assumes the role of Group CEO immediately and will be based at the headquarters of Adherium US in San Mateo, CA.

You may also like